Vanguard Group Inc. Increases Stock Holdings in AnaptysBio, Inc. (NASDAQ:ANAB)

Vanguard Group Inc. grew its position in shares of AnaptysBio, Inc. (NASDAQ:ANAB) by 8.4% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,843,740 shares of the biotechnology company’s stock after buying an additional 143,584 shares during the quarter. Vanguard Group Inc. owned 6.06% of AnaptysBio worth $24,411,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. JPMorgan Chase & Co. increased its stake in AnaptysBio by 191.4% in the third quarter. JPMorgan Chase & Co. now owns 33,744 shares of the biotechnology company’s stock valued at $1,130,000 after acquiring an additional 22,164 shares during the last quarter. Victory Capital Management Inc. increased its position in shares of AnaptysBio by 41.0% during the fourth quarter. Victory Capital Management Inc. now owns 334,450 shares of the biotechnology company’s stock valued at $4,428,000 after buying an additional 97,200 shares during the period. Y Intercept Hong Kong Ltd bought a new position in shares of AnaptysBio in the 4th quarter worth approximately $311,000. Geode Capital Management LLC lifted its position in AnaptysBio by 3.0% during the third quarter. Geode Capital Management LLC now owns 465,401 shares of the biotechnology company’s stock valued at $15,594,000 after buying an additional 13,336 shares during the period. Finally, AlphaQuest LLC grew its holdings in AnaptysBio by 1,891.5% in the fourth quarter. AlphaQuest LLC now owns 4,461 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 4,237 shares during the period.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ANAB. Truist Financial decreased their price objective on shares of AnaptysBio from $30.00 to $20.00 and set a “hold” rating for the company in a report on Wednesday, December 18th. Guggenheim reissued a “buy” rating on shares of AnaptysBio in a report on Monday, March 3rd. Wedbush reaffirmed an “outperform” rating and issued a $40.00 price objective on shares of AnaptysBio in a research note on Wednesday, February 12th. HC Wainwright reaffirmed a “neutral” rating and set a $22.00 target price on shares of AnaptysBio in a research note on Tuesday, March 4th. Finally, Wolfe Research assumed coverage on shares of AnaptysBio in a report on Tuesday, February 4th. They issued an “outperform” rating and a $25.00 price target for the company. Four analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $35.11.

AnaptysBio Price Performance

Shares of NASDAQ:ANAB opened at $18.10 on Wednesday. The firm has a market capitalization of $555.07 million, a PE ratio of -2.98 and a beta of -0.09. AnaptysBio, Inc. has a 1 year low of $12.21 and a 1 year high of $41.31. The firm’s 50-day moving average is $17.39 and its two-hundred day moving average is $20.27.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.72) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.61) by $0.89. The company had revenue of $43.11 million for the quarter, compared to the consensus estimate of $10.17 million. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. Analysts expect that AnaptysBio, Inc. will post -6.08 EPS for the current fiscal year.

AnaptysBio announced that its board has initiated a stock repurchase program on Monday, March 24th that allows the company to repurchase $75.00 million in shares. This repurchase authorization allows the biotechnology company to reacquire up to 13.1% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company’s leadership believes its shares are undervalued.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.